Roche cuts bait on late-stage study of Huntington's med tominersen, an Ionis import with prior safety flags
Hoping to tackle the absolutely brutal Huntington’s disease, Roche inked a licensing pact with Ionis back in 2017 for a novel antisense therapy targeting a protein implicated in the disease. Now, after riding out earlier safety red flags, Roche is calling a late-stage study quits on a data committee’s orders.
Roche has halted dosing for its Phase III study of tominersen, an antisense drug targeting the huntingtin protein and a mutant variant, after an independent data committee “made its recommendation based on the investigational therapy’s potential benefit/risk profile for study participants,” the Swiss drug giant said.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.